TY - JOUR
T1 - First-line therapy for chronic phase CML
T2 - selecting the optimal BCR-ABL1-targeted TKI
AU - Saglio, Giuseppe
AU - Jabbour, Elias
N1 - Funding Information:
The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoints and medical expertise. Professional medical writing and editorial assistance was provided by Kelly M. Fahrbach, PhD, of StemScientific, an Ashfield Company, part of UDG Healthcare plc, funded by BMS. GS has acted as a consultant and a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. EJ has received honoraria from ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer.
Funding Information:
The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoints and medical expertise. Professional medical writing and editorial assistance was provided by Kelly M. Fahrbach, PhD, of StemScientific, an Ashfield Company, part of UDG Healthcare plc, funded by BMS.
Publisher Copyright:
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/7/3
Y1 - 2018/7/3
N2 - Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line therapy can be difficult as both the unique characteristics of each TKI and patient need to be taken into account to find the optimal match. Patient characteristics include comorbidities, concomitant medications, lifestyle, risk factors, BCR-ABL1 transcript type (e.g. b2a2 or b3a2) and additional chromosomal abnormalities. Just as patients differ, side effects, drug-drug interactions, administration plans, dosing schedules and treatment-related expenses across TKIs also vary. Alignment of these characteristics with the appropriate TKI is key to successfully initiating CML treatment. Continued success relies on communication between the patient and the healthcare team, adherence and optimization of therapy once it is initiated. In this review, we discuss these factors, in addition to TKI efficacy and safety, the cost of therapy, the future of treating CML and treatment-free remission.
AB - Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line therapy can be difficult as both the unique characteristics of each TKI and patient need to be taken into account to find the optimal match. Patient characteristics include comorbidities, concomitant medications, lifestyle, risk factors, BCR-ABL1 transcript type (e.g. b2a2 or b3a2) and additional chromosomal abnormalities. Just as patients differ, side effects, drug-drug interactions, administration plans, dosing schedules and treatment-related expenses across TKIs also vary. Alignment of these characteristics with the appropriate TKI is key to successfully initiating CML treatment. Continued success relies on communication between the patient and the healthcare team, adherence and optimization of therapy once it is initiated. In this review, we discuss these factors, in addition to TKI efficacy and safety, the cost of therapy, the future of treating CML and treatment-free remission.
KW - Myeloid leukemias and dysplasias
KW - myeloproliferative disorders
KW - signaling therapies
UR - http://www.scopus.com/inward/record.url?scp=85030567360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030567360&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1379074
DO - 10.1080/10428194.2017.1379074
M3 - Review article
C2 - 28972424
AN - SCOPUS:85030567360
SN - 1042-8194
VL - 59
SP - 1523
EP - 1538
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -